Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma

• DOI: 10.1111/cen.13297
• Publication Date: 2016-12-28T01:52:40Z
• Authors: D.L. Morganstein; Z. Lai; L. Spain; S. Diem; D. Levine; C. Mace; M. Gore; J. Larkin
• Keywords: Subclinical infection

Checkpoint inhibitors are emerging as important cancer therapies but associated with a high rate of immune side effects, including endocrinopathy.To determine the burden thyroid dysfunction in patients melanoma treated checkpoint and describe clinical course.Consecutive either ipilimumab, nivolumab, pembrolizumab or combination ipilimumab nivolumab were identified. Baseline function tests used to exclude those pre-existing abnormalities, during treatment identify dysfunction.Rates overt keeping published phase 3 trials. Hypothyroidism occurred 13·0% programmed death receptor-1 (PD-1) inhibitor 22·2% PD-1 ipilimumab. Transient subclinical hyperthyroidism was observed inhibitor, 15·9% following investigations suggesting thyroiditic mechanism rather than Graves' disease, frequency subsequent hypothyroidism. Any abnormality 23·0% 39·1% 50% treatment. Abnormal more common female patients.Thyroid occurs commonly inhibitors, rates, dysfunction, occurring up 50%.